Wandercraft announced the commercial launch of its Atalante exoskeleton designed for stroke rehabilitation.
Wandercraft, a manufacturer of healthcare exoskeletons, announced the commercial launch of its Atalante rehabilitation walk exoskeleton at the American Physical Therapy Association conference in San Diego, Calif.
“This is a key milestone in Wandercraft’s life,” said Matthieu Masselinhe, chief executive officer of Wandercraft. “For many years, we have shared our development roadmap with many leading rehabilitation hospital teams in the USA. Following their advice and feedback, Wandercraft’s team has designed a unique technology to improve rehabilitation care. Atalante is highly successful in Europe, and we believe it will thrive in the innovation-prone USA market.’
Atalante was CE-marked in 2019 and cleared in December 2022 by the US Food and Drug Administration (FDA) in the stroke indication.
Every year, more than 795,000 people in the United States have a stroke, a leading cause of serious long-term disability. It has already been used to treat thousands of patients with various medical conditions across European rehabilitation hospitals.
Atalante enables hands-free, early, intensive, task-oriented walk and balance rehabilitation treatments. It is initially used for post-stroke patients.
Atalante’s self-balancing feature lets patients move in multiple directions hands-free, without an assistive device, and includes a dynamic balance mode that Wandercraft says is unique in the exoskeleton market.
Photo courtesy of Wandercraft
